Comparative Effectiveness of Medical Therapy, Percutaneous Revascularization, and Surgical Coronary Revascularization in Cardiovascular Risk Subgroups of Patients With CKD: A Retrospective Cohort Study of Medicare Beneficiaries
ConclusionsOutcomes associated with cardiovascular therapies among patients with CKD differed by baseline cardiovascular risk. Coronary revascularization was not associated with improved survival in low-risk patients, but was associated with improved survival in high-risk patients despite a greater observed rate of kidney failure. These findings may inform clinical decision making in the care of patients with both CKD and cardiovascular disease.
Around 850 million people currently are affected by different types of kidney disorders.1 Up to 1 in 10 adults worldwide has chronic kidney disease (CKD), which is invariably irreversible and mostly progressive. The global burden of CKD is increasing, and CKD is projected to become the fifth most common cause of years of life lost globally by 2040.2 If CKD remains uncontrolled and if the affected person survives the ravages of cardiovascular and other complications of the disease, CKD progresses to end-stage kidney disease, where life cannot be sustained without dialysis therapy or kidney transplantation.
Potassium channels are important to control membrane potential and drive epithelial transport processes. In this issue of Kidney International, Bignon et al. report the role of the Kir4.2 K+-channel, localized at the basolateral membrane of proximal tubules, in the reabsorption of bicarbonate and the modulation of renal ammoniagenesis. The findings have implications for our understanding of how the kidney reacts to hypokalemia, an acid load, and th e metabolic acidosis of patients with advanced stages of chronic kidney disease.
With increasing incidence and a prevalence of>10% among adults worldwide, chronic kidney disease (CKD) represents a major public health issue.1 CKD can lead to metabolic disorders and progress to end-stage kidney disease, and it increases the risk for cardiovascular disease and mortality. Our limited understanding of CKD pathophysiology and the mechanisms influencing kidney function in the healthy range represents a major barrier to the development of treatments targeting the causes rather than the symptoms of CKD.
[Vanguard] In recent times, the number of people coming down with kidney disease has been on the increase and many reasons have been adduced to explain the rise in number of cases. Chief among the reasons are the rise in cases of diabetes and high blood pressure; which experts say, increase the risk of chronic kidney disease. However, one disease which experts say could lead to kidney failure, respiratory disease, meningitis, liver failure and even death if left untreated, is little known leptospirosis, considered th
(World Scientific) A search using medical data bases reveals that hundreds of meta-analysis papers conducted with tens of millions of people worldwide have confirmed clinically the efficacies of 30 antioxidant-rich foods to prevent or treat chronic diseases, including hypertension, diabetes, cardiovascular disease, cognitive impairment, chronic kidney disease, cancer, and more. Professor Monte Lai, former professor of biophysics at the Medical College of Wisconsin talks about this and more in his new book 'The Food Cure.'
ConclusionHigh salt downregulated Nrf2 mainly via a sodium-dependent manner in kidney collecting duct cells, which might contribute to the excessive renal oxidative stress and CKD progression.
Those who consume up to 20 drinks per week are less likely to develop chronic kidney disease than never drinkers, but authors warn"potential benefits" of alcohol must be weighed against"harms."Medscape Medical News
The agreement is for Desidustat, a novel oral HIF-PH inhibitor for the treatment of anemia in patients with Chronic Kidney Disease (CKD) not-on-dialysis and for the treatment of anemia CKD patients on dialysis in Greater China, Zydus said in a statement. "Under the license agreement, CMS will pay Zydus an initial upfront payment," it added.
ConclusionsBoth models described imipenem popPK well; the parameter estimates were comparable and the included covariate was identical. However, estimated BSV was higher in the nonparametric model. This may have consequences for estimated exposure during dosing simulations and should be further investigated in simulation studies.